Drugs / NEDOMETINIB
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05195762 | Jun 2023 → Jun 2024 | nevus, epidermal | Albert Chiou | Withdrawn | No outcome recorded |
| Phase 2 | NCT05005845 | Sep 2021 → Oct 2023 | neurofibroma, neurofibromatosis type 1 | NFlection Therapeutics, Inc. | Completed | Met primary |
| Phase 2 | NCT04435665 | Aug 2020 → Apr 2021 | neurofibroma, neurofibromatosis type 1 | NFlection Therapeutics, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-01 | NFlection Therapeutics, Inc. | Results NFlection Therapeutics Announces Publication of Clinical Data Demonstrating the Effect of NFX-179 Topical MEK Inhibitor on Cutaneous Neurofibromas in Persons with Neurofibromatosis Type 1 nflection.com ↗
Twenty percent of cNF tumors treated with 0.5% NFX-179 Topical Gel had a ≥50% reduction in volume that is considered clinically meaningful, versus 6% in the vehicle group (P = 0.021, ANOVA). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-05-01 | NFlection Therapeutics, Inc. | NFlection Therapeutics Announces Publication of Clinical Data Demonstrating the Effect of NFX-179 Topical MEK Inhibitor on Cutaneous Neurofibromas in Persons with Neurofibromatosis Type 1 nflection.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NEDOMETINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067967 ↗ |
| Known as | NFX-179 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05195762 ↗ |
| Action | Inhibit | “a selective mitogen-activated protein kinase kinase (MEK) inhibitor (NFX-179)” NCT05195762 ↗ |
| Modality | Small molecule | — CHEMBL6067967 ↗ |
| Route | Topical | “NFX-179 Gel for topical administration, once daily for 28 days” NCT04435665 ↗ |